These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33882908)

  • 1. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
    Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
    J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway.
    Refaie MMM; El-Hussieny M; Bayoumi AMA; Abdelraheem WM; Abdel-Hakeem EA; Shehata S
    Eur J Pharmacol; 2024 Sep; 979():176834. PubMed ID: 39038638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
    Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
    J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
    Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
    Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
    Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.